4-(3,4-Dichloro Phenyl)-Tetralone | CAS:79560-19-3

We serve 4-(3,4-Dichloro Phenyl)-Tetralone CAS:79560-19-3 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
4-(3,4-Dichloro Phenyl)-Tetralone

Chemical Name:4-(3,4-Dichloro Phenyl)-Tetralone
CAS.NO:79560-19-3
Synonyms:4-(3,4-Dichloro Phenyl)-Tetralone
4-(3,4-Dichlorophenyl)-1-tetralone
4-(3,4-Dichlorophenyl)-3,4-dihydro-1(2H)-naphtalene-1-one
4-(3,4-Dichlorophenyl)-3,4-dihydronaphthalen-1(2H)-one
4-(3,4-dichlorophenyl)-3,4-dihydro-1(2H)-naphthalenone
 
Physical and Chemical Properties:
Density 1.3±0.1 g/cm3
Boiling Point 403.0±45.0 °C at 760 mmHg
Melting Point 97-99ºC
Molecular Formula C16H12Cl2O
Molecular Weight 291.172
Flash Point 170.3±29.3 °C
 
Specification:
Appearance:White to off-white powder
Assay:≥98.0%
elting Point:97-99ºC
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Sertraline hydrochloride(CAS:79559-97-0).



Contact us for information like 4-(3,4-Dichloro Phenyl)-Tetralone chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4-(3,4-dichlorophenyl)-3,4-dihydro-1(2H)-naphthalenone physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4-(3,4-Dichloro Phenyl)-Tetralone Use and application,4-(3,4-Dichlorophenyl)-1-tetralone technical grade,usp/ep/jp grade.


Related News: The government is leveraging its large patient population to push non-domestic drugs companies to cut prices to their lowest level globally.N1-(2-(dimethylamino)ethyl)-5-methoxy-N1-methyl-N4-(4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)benzene-1,2,4-triamine manufacturer The government is leveraging its large patient population to push non-domestic drugs companies to cut prices to their lowest level globally.N-Carbobenzyloxy-L-valine supplier The rigosertib Pre-approval Access Program is expected to launch in first half of 2020 and will allow Inceptua to supply intravenous rigosertib within designated countries, primarily and initially concentrated in selected countries in Europe, in response to physician requests for patients with higher-risk MDS who have exhausted all available treatment options, and are not eligible for or have no access to the INSPIRE study.(3R,4S)-1-benzoyl-4-phenyl-3-triethylsilyloxyazetidin-2-one vendor DPH and BPHC continue to work closely with the CDC to maintain vigilance during this virus outbreak.Resonant exploits its proprietary IMPaCT tumor microenvironment models and data platform to discover novel, unappreciated targets and functionally active anti-tumor antibodies for difficult to treat tumors.